BPMC News and Press, Blueprint Medicines Corporation From 01/11/21

Blueprint Medicines ([[BPMC]] -1.1%) promoted Andy Boral, M.D., Ph.D. to EVP, Clinical Development from his current chief medical officer position.Becker Hewes, M.D. will be named chief medical officer.Marion Dorsch, Ph.D., Chief Scientific Officer, has resigned from the company, ef...

Blueprint Medicines Announces R&D Leadership Transitions Blueprint Medicines Announces R&D Leadership Transitions -- Becker Hewes, M.D., promoted to Chief Medical Officer -- -- Andy Boral, M.D., Ph.D., to transition from Chief Medical Officer to Executive Vice Pr...

Blueprint Medicines Reports Portfolio Milestones and Outlines 2021 Roadmap for Precision Medicine Leadership -- AYVAKIT™ (avapritinib) granted FDA breakthrough therapy designation for the treatment of moderate to severe indolent systemic mastocytosis -- -- Positive to...

Cogent Biosciences (COGT) is up +3.8% after Piper Sandler initiated the coverage with an overweight rating on the stock. The price target at $22 per share is +80.3% to yesterday’s close.Noting that the ‘risk/reward now meaningfully skews to the upside after the company...

Blueprint Medicines (BPMC) has submitted a supplemental new drug application to the FDA seeking approval for Ayvakit (avapritinib) for the treatment of adult patients with advanced systemic mastocytosis ((SM)), a rare disorder characterized by the uncontrolled proliferation and activation of ...

Blueprint Medicines Submits Supplemental New Drug Application to FDA for AYVAKIT™ (avapritinib) for the Treatment of Advanced Systemic Mastocytosis CAMBRIDGE, Mass. , Dec. 17, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision th...

Halvorsen's 13F portfolio value increased from $23.14B to $27.68B. The number of positions increased 71 to 86. Viking Global increased Microsoft, Mecadolibre, and CME Group while reducing Amazon.com and dropping Uber Technologies & JD.com. The top three positions are Microsoft...

Blueprint Medicines Data Presented at 62nd ASH Annual Meeting and Exposition Highlight Broad Commitment to Advance Patient Care in Systemic Mastocytosis CAMBRIDGE, Mass. , Dec. 7, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision thera...

Blueprint Medicines ([[BPMC]] -2.5%) and collaboration partner Roche ([[RHHBY]] +2.1%) announce the FDA nod for Gavreto (pralsetinib) for the treatment of advanced/metastatic RET fusion-positive medullary thyroid cancer in patients at least 12 years old who require systemic therapy and who ar...

Blueprint Medicines Announces FDA Approval of GAVRETO™ (pralsetinib) for the Treatment of Patients with Advanced or Metastatic RET-Mutant and RET Fusion-Positive Thyroid Cancer CAMBRIDGE, Mass. , Dec. 1, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (N...